识别与优化用于子宫内膜日期判定的基因表达特征
该多中心前瞻性研究于2018年7月至2020年10月在西班牙同一集团的五家中心招募281例患者,最终对225例接受IVF治疗的高加索裔患者进行基因表达分析,其中217例数据用于构建预测模型。研究开发了基于73个基因的TED特征,在独立测试集中对分泌期子宫内膜(尤其种植窗)的预测能力最佳,并在多个数据集中表现一致。作者指出需进一步研究确认子宫内膜日期判定方法的临床实用性及TED的具体应用。
要点
- 基于73个基因的TED特征在独立测试集中对分泌中期子宫内膜分期预测能力最佳。
- TED特征在多个全转录组数据集中预测表现一致,常优于已发表的基因集。
- 作者指出需进一步研究确认子宫内膜日期判定方法整体及TED的临床实用性。
核心结论
- 多种基因表达特征组合可作为子宫内膜日期判定的生物标志物,但预测性能可变,取决于模型中基因的数量和身份、数据集特征及测量基因表达的技术。
- 基于73个基因的TED特征为分泌期进展(尤其分泌中期)提供了一致日期判定的增强工具。
研究设计与样本
- 多中心前瞻性研究,2018年7月至2020年10月在西班牙同一集团的五家中心进行,招募281例患者。
- 最终纳入225例接受IVF治疗的高加索裔患者进行基因表达分析,预处理和批次效应过滤后217例患者数据结合人工智能算法(支持向量机、随机森林和k近邻)评估不同预测模型。
- 另分析基因表达综合数据库(GEO)中137名女性的分泌期子宫内膜转录组,研究基因独立及按特征分组的日期判定能力。
- 子宫内膜活检使用靶向TruSeq(Illumina)定制RNA表达面板(ED panel),包含301个基因。
- 最终样本(n=217)分为训练集用于特征发现和独立测试集用于评估新特征的预测性能。
主要发现
- ED panel测试开发了基于73个基因新特征(称为TED)的模型,在独立测试集中对分泌期子宫内膜分期(尤其种植窗,孕酮给药平均114.5±7.2小时,患者范围82-172小时)显示最佳预测能力。
- TED特征在所有评估的数据集中表现一致优异,常以更少基因优于先前发表的基因集。
- 多种基因特征组合可提供足够的子宫内膜日期判定,但预测性能取决于所包含基因的身份、基因表达平台、所用算法和数据集特征。
临床怎么用
- 作者指出需进一步研究确认子宫内膜日期判定方法整体是否具有临床实用性,并指导TED在临床环境中的具体使用。
局限性
- 尽管子宫内膜活检日期判定对研究子宫内膜进展和容受性过程至关重要,但需进一步研究确认子宫内膜日期判定方法整体是否具有临床实用性,并指导TED在临床环境中的具体使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What are the key considerations for developing an enhanced transcriptomic method for secretory endometrial tissue dating? SUMMARY ANSWER: Multiple gene expression signature combinations can serve as biomarkers for endometrial dating, but their predictive performance is variable and depends on the number and identity of the genes included in the prediction model, the dataset characteristics and the technology employed for measuring gene expression. WHAT IS KNOWN ALREADY: Among the new generation of transcriptomic endometrial dating (TED) tools developed in the last decade, there exists variation in the technology used for measuring gene expression, the gene makeup and the prediction model design. A detailed study, comparing prediction performance across signatures for understanding signature behaviour and discrepancies in gene content between them, is lacking. STUDY DESIGN, SIZE, DURATION: A multicentre prospective study was performed between July 2018 and October 2020 at five different centres from the same group of clinics (Spain). This study recruited 281 patients and finally included in the gene expression analysis 225 Caucasian patients who underwent IVF treatment. After preprocessing and batch effect filtering, gene expression measurements from 217 patients were combined with artificial intelligence algorithms (support vector machine, random forest and k-nearest neighbours) allowing evaluation of different prediction models. In addition, secretory-phase endometrial transcriptomes from gene expression omnibus (GEO) datasets were analysed for 137 women, to study the endometrial dating capacity of genes independently and grouped by signatures. This provided data on the consistency of prediction across different gene expression technologies and datasets. PARTICIPANTS/MATERIALS, SETTING, METHODS: Endometrial biopsies were analysed using a targeted TruSeq (Illumina) custom RNA expression panel called the endometrial dating panel (ED panel). This panel included 301 genes previously considered relevant for endometrial dating as well as new genes selected for their anticipated value in detecting the secretory phase. Final samples (n = 217) were divided into a training set for signature discovery and an independent testing set for evaluation of predictive performance of the new signature. In addition, secretory-phase endometrial transcriptomes from GEO were analysed for 137 women to study endometrial dating capacity of genes independently and grouped by signatures. Predictive performance among these signatures was compared according to signature gene set size. MAIN RESULTS AND THE ROLE OF CHANCE: Testing of the ED panel allowed development of a model based on a new signature of 73 genes, which we termed 'TED' and delivers an enhanced tool for the consistent dating of the secretory phase progression, especially during the mid-secretory endometrium (3-8 days after progesterone (P) administration (P + 3-P + 8) in a hormone replacement therapy cycle). This new model showed the best predictive capacity in an independent test set for staging the endometrial tissue in the secretory phase, especially in the expected window of implantation (average of 114.5 ± 7.2 h of progesterone administered; range in our patient population of 82-172 h). Published sets of genes, in current use for endometrial dating and the new TED genes, were evaluated in parallel in whole-transcriptome datasets and in the ED panel dataset. TED signature performance was consistently excellent for all datasets assessed, frequently outperforming previously published sets of genes with a smaller number of genes for dating the endometrium in the secretory phase. Thus, this optimized set exhibited prediction consistency across datasets. LARGE SCALE DATA: The data used in this study is partially available at GEO database. GEO identifiers GSE4888, GSE29981, GSE58144, GSE98386. LIMITATIONS, REASONS FOR CAUTION: Although dating the endometrial biopsy is crucial for investigating endometrial progression and the receptivity process, further studies are needed to confirm whether or not endometrial dating methods in general are clinically useful and to guide the specific use of TED in the clinical setting. WIDER IMPLICATIONS OF THE FINDINGS: Multiple gene signature combinations provide adequate endometrial dating, but their predictive performance depends on the identity of the genes included, the gene expression platform, the algorithms used and dataset characteristics. TED is a next-generation endometrial assessment tool based on gene expression for accurate endometrial progression dating especially during the mid-secretory. STUDY FUNDING/COMPETING INTEREST(S): Research funded by IVI Foundation (1810-FIVI-066-PD). P.D.-G. visiting scientist fellowship at Oxford University (BEFPI/2010/032) and Josefa Maria Sanchez-Reyes' predoctoral fellowship (ACIF/2018/072) were supported by a program from the Generalitat Valenciana funded by the Spanish government. A.D.-P. is supported by the FPU/15/01398 predoctoral fellowship from the Ministry of Science, Innovation and Universities (Spanish Government). D.W. received support from the NIHR Oxford Biomedical Research Centre. The authors do not have any competing interests to declare.
引用
- Diaz-Gimeno P, Sebastian-Leon P, Sanchez-Reyes JM, et al. Identifying and optimizing human endometrial gene expression signatures for endometrial dating. Hum Reprod. 2022. PMID: 34875061. doi:10.1093/humrep/deab262
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。